Compile Data Set for Download or QSAR
Report error Found 211 Enz. Inhib. hit(s) with all data for entry = 2755
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378995(US10266548, Example 4-1 | Preparation of {3-[({2-[...)
Affinity DataIC50: 2.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378915(US10266548, Example 2-1-1 | 2-[1-(6-chloro-2-fluor...)
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378932(US10266548, Example 2-2-1 | 2-[1-(6-chloro-2- fluo...)
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379026(US10266548, Example 7-1 | Preparation of 1-[3,5-di...)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379006(US10266548, Example 4-2-1 | {3[({2-[1-(2- fluorobe...)
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379042(US10266548, Example 13-1 | Preparation of 2-({2-[1...)
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379107(Preparation of 5-(2-aminoethoxy)-2-[1-(4-ethoxy-2,...)
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379108(2-[1-(4-ethoxy-2,6- difluorobenzyl)-1H- indazol-3-...)
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379024(US10266548, Example 6-1 | Preparation of 2-[1-(4-c...)
Affinity DataIC50: 3.90nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378946(US10266548, Example 2-3-1 | 2-[1-(2-chloro- 4,5- d...)
Affinity DataIC50: 4.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378960(US10266548, Example 2-4-1 | 2-[1-(2,6- difluoro-3-...)
Affinity DataIC50: 4.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378973(US10266548, Example 2-5-1 | 2-[1-(4-ethoxy- 2,6- d...)
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379040(US10266548, Example 12-2 | US10266548, Example 15-...)
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379040(US10266548, Example 12-2 | US10266548, Example 15-...)
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378980(US10266548, Example 2-6-1 | 2-[1-(2-chloro-4- meth...)
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378991(US10266548, Example 3-1 | Preparation of 2-[1-(4-e...)
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379045(4-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-(2...)
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378982(US10266548, Example 2-7-1 | 2-[1-(2,6- difluoroben...)
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379041(US10266548, Example 12-3 | US10266548, Example 15-...)
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379103(US10266548, Example 36-1 | US10266548, Example 36-...)
Affinity DataIC50: 4.91nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379085(4-({2-[1-(2,6- difluoro-4- hydroxybenzyl)-1H- inda...)
Affinity DataIC50: 5.03nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379021(US10266548, Example 5-1 | Preparation of 2-[1-(4-e...)
Affinity DataIC50: 5.20nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379049(Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...)
Affinity DataIC50: 5.20nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379019(US10266548, Example 4-9 | 1-({2-[1-(4- ethoxy-2,6-...)
Affinity DataIC50: 5.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379083(4-({5-methoxy-2-[1- (4-propylbenzyl)- 1H-indazol-3...)
Affinity DataIC50: 5.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378971(US10266548, Example 2-48-1 | 2-[1-(2,6- difluoro-3...)
Affinity DataIC50: 5.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379041(US10266548, Example 12-3 | US10266548, Example 15-...)
Affinity DataIC50: 5.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378958(US10266548, Example 2-39-1 | 2-{1-[4- (difluoro- m...)
Affinity DataIC50: 5.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379042(US10266548, Example 13-1 | Preparation of 2-({2-[1...)
Affinity DataIC50: 5.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379106(Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...)
Affinity DataIC50: 5.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379004(US10266548, Example 4-18 | formic acid - (5S)-5-[(...)
Affinity DataIC50: 5.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379004(US10266548, Example 4-18 | formic acid - (5S)-5-[(...)
Affinity DataIC50: 5.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379103(US10266548, Example 36-1 | US10266548, Example 36-...)
Affinity DataIC50: 6.20nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379064(({2-[1-(4-ethoxy- 2,6- difluorobenzyl)- 1H-indazol...)
Affinity DataIC50: 6.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379103(US10266548, Example 36-1 | US10266548, Example 36-...)
Affinity DataIC50: 6.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379046(4-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-(2...)
Affinity DataIC50: 6.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378917(US10266548, Example 2-10-1 | 2-[1-(2- chlorobenzyl...)
Affinity DataIC50: 6.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378985(US10266548, Example 2-8-1 | 2-[1-(2,3- difluoro-4-...)
Affinity DataIC50: 6.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378988(US10266548, Example 2-9-1 | US10266548, Example 15...)
Affinity DataIC50: 6.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379112(Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...)
Affinity DataIC50: 6.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378919(US10266548, Example 2-11-1 | methyl 3-chloro- 4-({...)
Affinity DataIC50: 7.10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379043(2-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 4-(p...)
Affinity DataIC50: 7.20nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378921(US10266548, Example 2-12-1 | 2-[1-(4-bromo- 2,6- d...)
Affinity DataIC50: 7.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378988(US10266548, Example 2-9-1 | US10266548, Example 15...)
Affinity DataIC50: 7.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379003(US10266548, Example 4-17 | 2-[2-({2-[1-(4- ethoxy-...)
Affinity DataIC50: 7.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379003(US10266548, Example 4-17 | 2-[2-({2-[1-(4- ethoxy-...)
Affinity DataIC50: 7.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379025(US10266548, Example 6-2 | 2-(1-{2,6-difluoro- 4-[(...)
Affinity DataIC50: 7.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379027(US10266548, Example 8-1 | US10266548, Example 15-5...)
Affinity DataIC50: 7.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM379008(US10266548, Example 4-3)
Affinity DataIC50: 7.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Intellectual Property

US Patent
LigandPNGBDBM378999(US10266548, Example 4-13 | 2-[1-(2- fluorobenzyl)-...)
Affinity DataIC50: 7.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 211 total ) | Next | Last >>
Jump to: